The FDA's First 'No' on Scholar Rock Was Never About the Drug — Now the Approval Is Priced and the Launch Isn't

The FDA cleared Scholar Rock's SMA drug apitegromab ahead of its September 30 deadline, and the stock jumped in after-hours trading. Against the near-miss that happened a year before, that early green light reads like a rescue. It was mostly a scheduling fix. To decide what the approval is worth now, you have to separate what the FDA actually objected to last year from what investors feared it meant.

Why the first "no" was never about the science

Spinal muscular atrophy is a genetic disease that robs patients of a protein called SMN, and slowly weakens muscles. The standard treatments — Biogen's Spinraza, Roche's Evrysdi, Novartis's Zolgensma — target the disease's cause by restoring that protein. Apitegromab attacks the problem from the other end: instead of fixing the nerve signal, it inhibits myostatin, a protein that restrains muscle growth. It's a muscle-targeted add-on meant to be stacked on top of the gene fix, which is a genuinely different and complementary mechanism.

In September 2025 the FDA handed Scholar Rock a Complete Response Letter — effectively a rejection that stops an application in its tracks — for apitegromab. Investors read that as a grave verdict on the drug and marked the stock down. That reading was the error, and it's the whole reason the setup worked. The CRL cited observations from a routine inspection of Catalent Indiana, a contract fill-finish facility now owned by Novo Nordisk, that is not even specific to apitegromab. It did not question the drug's efficacy or safety at all.

That is the distinction between a structural problem and a growing pain, and you can tell them apart by asking a simple question: is the issue in the product or in the logistics around it? A rejection for manufacturing observations at a third-party plant means the drug is approvable and someone else's cleanroom wasn't up to standard. It's a genuine, fixable setback — a supply problem, not a product problem.

How a fix became an early approval

Scholar Rock responded the way the evidence demanded: it qualified a second U.S. fill-finish facility with a clean inspection record, then resubmitted the application in March 2026 with that second plant added to its manufacturing plan. The FDA accepted the filing, set a September 30 action date, and — after the original contract plant's April inspection was classified as "Official Action Indicated" — let the review progress on the second facility alone, with commercial drug already sitting at a packaging provider ready for launch.

There is a useful lesson in the timing itself. The FDA cleared apitegromab before the deadline a year after flagging a manufacturing observation at a Novo Nordisk-owned plant. That sequence is essentially the company's own proof that its science was never in question. The approvability bin of risk — the thing that caused the September 2025 selloff — is now closed.

The approval is priced; the launch is not

Here is where the math has to take over from the story. Scholar Rock is pre-revenue and unprofitable, so the usual earnings multiples do not apply. The forward yardstick for a single-asset biotech is peak sales. Truist, after the positive Phase 3 data, put apitegromab's potential at about $1.2 billion in peak annual U.S. sales, and the broader analyst range runs to roughly $1.5 billion.

Against that, the company trades at a market cap of about $6.7 billion. That is roughly 5.5 to 5.6 times the low end of peak-sales estimates for a drug that is only now starting to be sold. For a de-risked rare-disease product, that is not a distressed price; it is a launch-stage multiple that capitalizes most of the consensus peak before a single month of revenue exists.

That reframing is the practical point. The low-risk trade, buying the September 2025 dip on a manufacturing-only rejection, has matured into something different. The remaining return is no longer regulatory — it's operational: what price Scholar Rock sets, whether payers cover it, how fast non-ambulatory adult and child patients actually get it, and whether the muscle-targeted add-on wins prescriptions over the gene-fix drugs it complements. With only about $437 million in cash, a roughly $297 million annual burn, and debt, the company is also now burning cash through a launch it will have to keep funding.

None of that argues the approval is meaningless. It argues that the event that just happened — the early FDA clearance — is what a year of evidence said it would be, and the market has sold the certainty at $55, near the top of its 52-week range. The question investors should carry forward is no longer "will the FDA approve it?" That one is answered. It's whether Scholar Rock can convert a clean approval and a $1.2 billion peak into an actual launch that earns the multiple already assigned to it.